Kiniksa Pharmaceuticals International, plc (KNSA) Stock: Price, Forecast & Analyst Target
Kiniksa Pharmaceuticals International, plc (KNSA) — MoonshotScore 48/100 (Fair band), calculated Oct 5, 2026. Price $75.79 (+0.76%), as of the Oct 2, 2026 trading session; market cap $5.78B. Expected results Oct 27, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 10.99× (market value Oct 2, 2026; cash Jun 30, 2026) · expected results Oct 27, 2026
Kiniksa Pharmaceuticals International, plc · KNSA · NASDAQ · Healthcare · Medical - Pharmaceuticals
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Kiniksa Pharmaceuticals International (KNSA)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and elite growth — and it’s docked well below the pillars; verify the gap before trusting the setup. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $244M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 3 of 8
- Altman Z 15.69 · Piotroski F 6
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 48 | Fair | |
| 48 | Fair | |
| 47 | Fair | |
| 47 | Fair | |
| 47 | Fair | |
| 47 | Fair |
The score moved from 47 in the stored Oct 4, 2026 snapshot to 48 in the current publication computed Oct 5, 2026 (+1); the largest pillar moves were Financial Safety -1 and Momentum -1. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $75.79 | |
| Change on the day | +0.76% | |
| 52-week range | $35.20 – $82.94 | |
| Market capitalisation | $5.78B | |
| Price / earnings (trailing) | 70.83 | |
| Shares traded on the day | 376.3K | |
| Beta (volatility vs the S&P 500) | 0.09 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We anticipate a potential commercial launch of [ KPL-387 ] in the 2028 and 2029 time frame, extending our leadership in the recurring pericarditis market so it can help many more patients.
Sanj Patel · Statement from
I think, as you look throughout the rest of the year here, we don't provide specific gross to net guidance, but we do anticipate a co-pay support to continue to be favorable to gross to net on an annual basis, with the majority of the impact having taken place in the first quarter.
Mark Ragosa · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Kiniksa Pharmaceuticals International (KNSA): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 20, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 20, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 20, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the KNSA film — every key number, told as a short cinematic story
~2 min · open the film
What is Kiniksa Pharmaceuticals International (KNSA), and what does it report?
Short answer · as of
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. Kiniksa Pharmaceuticals International, plc (KNSA) is listed on NASDAQ. Healthcare / Medical Pharmaceuticals SEC filing business address: 105 Piccadilly, Second Floor, London, W1J 7NJ. It employs 366 people and is led by Sanj K. Patel. In Q2 FY2026 it reported revenue of $244M and net income of $25M. The market values it at $5.78B.
What do the latest results show for Kiniksa Pharmaceuticals International (KNSA)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $244M. Against analyst estimates the company has EPS beat 3 of 8 reports.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $243.60M Jun 30, 2026
- Latest quarter · R&D
- $40.90M Jun 30, 2026
- Latest quarter · SG&A
- $63.87M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $27.19M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $243.60M | $40.90M | $63.87M | $27.19M |
| Mar 31, 2026 | $214.27M | $27.48M | $61.15M | $29.27M |
| Dec 31, 2025 | $202.13M | $34.64M | $56.77M | $19.77M |
| Sep 30, 2025 | $180.85M | $24.14M | $49.10M | $24.02M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $243.60M Jul 28, 2026
- Latest report · revenue estimate
- $226.49M Jul 28, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 28, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 28, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 28, 2026 | $243.60M | $226.49M | $0.3000 | $0.2995 |
| Apr 28, 2026 | $214.27M | $206.11M | $0.2700 | $0.1800 |
| Feb 24, 2026 | $202.13M | $200.81M | $0.1700 | $0.2900 |
| Oct 28, 2025 | $180.85M | $197.09M | $0.2300 | $0.3300 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $244M | $25M | $0.30 (diluted) |
| Q1 FY2026 | $214M | $23M | $0.27 (diluted) |
| Q4 FY2025 | $202M | $14M | $0.18 (diluted) |
| Q3 FY2025 | $181M | $18M | $0.23 (diluted) |
What are the financial strengths and risks for Kiniksa Pharmaceuticals International (KNSA)?
Short answer
Cash and short-term investments were $525.93M at the Jun 30, 2026 balance-sheet date. Operating cash flow was $47.46M for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway. The MoonshotScore pillars rate business quality, balance-sheet strength, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 15.69 · Piotroski F 6. Trailing ratios: ROE 13.7% · ROA 9.0% · current ratio 3.90 · earnings yield 1.4% · free-cash-flow yield 3.2%.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
- Rich valuation — a P/E of 70.83 runs well above the Healthcare sector’s ~21.10x, leaving little room for a miss.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $47.46M Jun 30, 2026
- Previous quarter · operating cash flow
- $50.20M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $47.46M | −$660,000 |
| Mar 31, 2026 | $50.20M | −$160,000 |
| Dec 31, 2025 | $53.89M | −$630,000 |
| Sep 30, 2025 | $33.68M | −$670,000 |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Kiniksa Pharmaceuticals International (KNSA)?
Short answer · as of
The next earnings report is expected on Oct 27, 2026. Current published price targets run low $71.00 · high $99.00 · consensus $86.40 · median $90.00 against a quoted price of $75.79 (as of Oct 2, 2026).
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We anticipate a potential commercial launch of [ KPL-387 ] in the 2028 and 2029 time frame, extending our leadership in the recurring pericarditis market so it can help many more patients.
Sanj Patel ·
I think, as you look throughout the rest of the year here, we don't provide specific gross to net guidance, but we do anticipate a co-pay support to continue to be favorable to gross to net on an annual basis, with the majority of the impact having taken place in the first quarter.
Mark Ragosa ·
How does Kiniksa Pharmaceuticals International compare with its peers?
Short answer
Kiniksa Pharmaceuticals International's score ranks 4th of 11 in the bounded comparison shown, against 10 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $361.23 Oct 5, 2026 | $38.3B | 96 5-pillar Oct 5, 2026 | |
| $20.21 Oct 5, 2026 | $1.27B | 57 5-pillar Oct 5, 2026 | |
| $16.08 Oct 5, 2026 | $953M | 56 5-pillar Oct 5, 2026 | |
| Kiniksa Pharmaceuticals International (KNSA) — this page | $75.79 | $5.78B | 48 |
| $42.86 Oct 5, 2026 | $5.61B | 45 5-pillar Oct 5, 2026 | |
| $3.17 Oct 5, 2026 | $28.1M | 39 5-pillar Oct 5, 2026 | |
| $2.73 Oct 5, 2026 | $231M | 35 5-pillar Oct 5, 2026 | |
| $1.33 Oct 5, 2026 | $28.4M | 32 5-pillar Oct 5, 2026 | |
| $0.81 Oct 5, 2026 | $22.4M | 28 5-pillar Oct 5, 2026 | |
| $6.27 Oct 5, 2026 | $25.5M | 27 5-pillar Oct 5, 2026 | |
| $22.83 Oct 5, 2026 | $155M | 21 5-pillar Oct 5, 2026 | |
| $221.38 Jan 8, 2026 | $5.61B | — Model unavailable | |
| $41.03 May 15, 2026 | $5.25B | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $71.00 – $99.00
- Consensus target
- $86.40
- Median target
- $90.00
Consensus record · Captured .
Measured against a quoted price of $75.79 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Sep 3, 2026
- Transactions
- 60
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 1
- Other transactions
- 59
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 61.5% Period end Jun 30, 2026
- Previous quarter · ownership
- 59.3% Prior to period end Jun 30, 2026
- Reporting holders
- 276 Period end Jun 30, 2026
- Previous quarter · holders
- 234 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 6,971,361 |
| Rubric Capital Management LP | 3,999,800 |
| Baker Bros. Advisors LP | 2,834,643 |
| Blackrock, INC. | 2,739,615 |
| Tang Capital Management LLC | 2,259,889 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Kiniksa Pharmaceuticals International (KNSA)?
Kiniksa Pharmaceuticals International Healthcare Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the KNSA research dossier (written May 4, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for KNSA?
KNSA carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is KNSA a good stock to buy?
Stock Expert AI does not rate KNSA buy, sell or hold. Kiniksa Pharmaceuticals International, plc carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the KNSA stock price today?
The last price recorded on this page for Kiniksa Pharmaceuticals International, plc (KNSA) is $75.79, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the KNSA price target?
The analyst consensus price target for Kiniksa Pharmaceuticals International, plc (KNSA) is $86.40 (range $71.00 to $99.00, median $90.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for KNSA?
Kiniksa Pharmaceuticals, Ltd. faces several risks inherent in the biopharmaceutical industry. Clinical trial risks are significant, as unfavorable outcomes can delay or halt the development of pipeline candidates. Regulatory risks include potential delays or rejections in the drug approval process. Competition from established therapies and new entrants poses a threat to market share.
What are the key factors to evaluate for KNSA?
Kiniksa Pharmaceuticals International, plc (KNSA) holds a MoonshotScore in the low range. P/E: 70.83x. Analysts target $86.40 (+14%). Not financial advice.
How frequently does KNSA data refresh on this page?
KNSA's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven KNSA's recent stock price performance?
Kiniksa Pharmaceuticals International, plc (KNSA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Approved product (ARCALYST) generating revenue. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KNSA overvalued or undervalued right now?
Kiniksa Pharmaceuticals International, plc (KNSA) trades at 70.83x earnings. Analysts target $86.40 (+14%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 4, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (88 figures)
The 88 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Sanj Patel (Jul 28, 2026): We anticipate a potential commercial launch of [ KPL-387 ] in the 2028 and 2029 time frame, extending our leadership in the recurring pericarditis market so it can help many more patients. Mark Ragosa (Jul 28, 2026): I think, as you look throughout the rest of the year here, we don't provide specific gross to net guidance, but we do anticipate a co-pay support to continue to be favorable to gross to net on an annual basis, with the majority of the impact having taken place in the first quarter. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | 105 Piccadilly, Second Floor, London, W1J 7NJ | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "105 Piccadilly, London, GL, W1J 7NJ, GB". |
FMP — 77 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Oct 27, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $75.79 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T20:04:47.546Z. | |
px.change | Change on the day | +0.76% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $5.78B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:01.000Z. Captured from FMP at 2026-10-04T20:04:46.454Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
id.business_summary | Business description (FMP excerpt) | Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | +$0.57 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $244M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | 70.83 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 376.3K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.09 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Medical Pharmaceuticals | FMP | Financial Modeling Prep (FMP) company profile — The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | |
id.employees | Employees | 366 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
id.ceo | Chief executive | Sanj K. Patel | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_income | Net income, Q2 FY2026 | $25M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $38.54M, net result −$157.92M; FY2022 revenue $220.18M, net result $183.36M; FY2023 revenue $270.26M, net result $14.08M; FY2024 revenue $423.24M, net result −$43.19M; FY2025 revenue $677.56M, net result $59.01M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Product $677.56M | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 54.5% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $243.60M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $40.90M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $63.87M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $27.19M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $214.27M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $27.48M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $61.15M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | $29.27M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $202.13M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $34.64M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $56.77M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $19.77M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $180.85M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $24.14M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $49.10M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | $24.02M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-07-28.revenue_actual | Revenue · reported — report date 2026-07-28 | $243.60M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-28.revenue_estimated | Revenue · estimate — report date 2026-07-28 | $226.49M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-28.eps_actual | EPS · reported — report date 2026-07-28 | $0.3000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-28.eps_estimated | EPS · estimate — report date 2026-07-28 | $0.2995 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-28.revenue_actual | Revenue · reported — report date 2026-04-28 | $214.27M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-28.revenue_estimated | Revenue · estimate — report date 2026-04-28 | $206.11M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-28.eps_actual | EPS · reported — report date 2026-04-28 | $0.2700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-28.eps_estimated | EPS · estimate — report date 2026-04-28 | $0.1800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-24.revenue_actual | Revenue · reported — report date 2026-02-24 | $202.13M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-24.revenue_estimated | Revenue · estimate — report date 2026-02-24 | $200.81M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-24.eps_actual | EPS · reported — report date 2026-02-24 | $0.1700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-24.eps_estimated | EPS · estimate — report date 2026-02-24 | $0.2900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.revenue_actual | Revenue · reported — report date 2025-10-28 | $180.85M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.revenue_estimated | Revenue · estimate — report date 2025-10-28 | $197.09M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.eps_actual | EPS · reported — report date 2025-10-28 | $0.2300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.eps_estimated | EPS · estimate — report date 2025-10-28 | $0.3300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $525.93M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $47.46M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $8.90M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 8.99× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $47.46M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | $50.20M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$660,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$160,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $53.89M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$630,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | $33.68M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$670,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt | Stored analyst price targets | low $71.00 · high $99.00 · consensus $86.40 · median $90.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $71.00 – $99.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $86.40 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $90.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 60 transactions · 0 purchases, 1 sales, 59 other transactions · 7 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Sep 3, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 61.5% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 59.3% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 276 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 234 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Fmr LLC — shares in provider snapshot | 6,971,361 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Rubric Capital Management LP — shares in provider snapshot | 3,999,800 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Baker Bros. Advisors LP — shares in provider snapshot | 2,834,643 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Blackrock, INC. — shares in provider snapshot | 2,739,615 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Tang Capital Management LLC — shares in provider snapshot | 2,259,889 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-04 | |
fin.scores | Distress and quality screens | Altman Z 15.69 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
px.range52 | 52-week range | $35.20 – $82.94 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 13.7% · ROA 9.0% · current ratio 3.90 · earnings yield 1.4% · free-cash-flow yield 3.2% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 10.99× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $525.93M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-07-28.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($243.60M) with the recorded estimate ($226.49M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-28.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.3000) with the recorded estimate ($0.2995) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 48 of 100 · Fair · pillars 90 / 94 / 41 / 98 / 92 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 47 (stored snapshot Oct 4, 2026) → 48 (current publication computed Oct 5, 2026) (+1) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-07-28. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-28.revenue_actual,earn.history.depth.2026-07-28.revenue_estimated,earn.history.depth.2026-07-28.revenue_actual.comparison,earn.history.depth.2026-07-28.eps_actual.comparison,earn.history.depth.2026-07-28.eps_actual,earn.history.depth.2026-07-28.eps_estimated,earn.history.depth.2026-04-28.revenue_actual,earn.history.depth.2026-04-28.revenue_estimated,earn.history.depth.2026-04-28.eps_actual,earn.history.depth.2026-04-28.eps_estimated,earn.history.depth.2026-02-24.revenue_actual,earn.history.depth.2026-02-24.revenue_estimated,earn.history.depth.2026-02-24.eps_actual,earn.history.depth.2026-02-24.eps_estimated,earn.history.depth.2025-10-28.revenue_actual,earn.history.depth.2025-10-28.revenue_estimated,earn.history.depth.2025-10-28.eps_actual,earn.history.depth.2025-10-28.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.